PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项多机构，I期，升级的安全性和耐受性的研究，每3周给予5天以上的非维甲酸治疗实体肿瘤。将测定MTD，并与单核细胞分析一起评估药代动力学。将尽可能评估肿瘤的反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-institutional, phase I,escalating study of safety and tolerability of IV fenretinide given over 5 days every 3 weeks in solid tumor malignanies. MTD will be determined and pharmacokinetics will be assessed along with mononuclear cell assays. Tumor response will be assessed whever possible.